bacteri
infect
respiratori
tract
constitut
major
caus
death
worldwid
given
constant
rise
bacteri
resist
antibiot
treatment
failur
increasingli
frequent
context
innov
therapeut
strategi
urgent
need
stimul
innat
immun
cell
respiratori
tract
via
activ
tolllik
receptor
tlr
attract
approach
rapidli
activ
bodi
immun
defens
broad
spectrum
microorgan
previou
studi
agonist
flagellin
anim
model
show
standalon
tlr
stimul
result
effect
treatment
pneumococc
respiratori
infect
significantli
improv
therapeut
outcom
concomit
antibiot
treatment
investig
antibacteri
interact
antibiot
intranas
flagellin
mous
model
pneumococc
respiratori
infect
use
variou
dose
oral
administ
amoxicillin
system
administ
cotrimoxazol
found
intranas
instil
flagellin
dose
promot
maxim
lung
proinflammatori
respons
induc
synergist
rather
addit
antibacteri
effect
antibioticsuscept
pneumococcu
next
set
model
infect
pneumococcu
resist
multipl
antibiot
context
influenza
superinfect
remark
combin
amoxicillin
flagellin
effect
treat
superinfect
amoxicillinresist
pneumococcu
sinc
bacteri
clearanc
increas
compar
standalon
treatment
result
also
show
respons
flagellin
lung
tissu
gener
innat
immun
respons
even
though
damag
influenza
viru
pneumococc
infect
conclus
demonstr
select
boost
lung
innat
immun
conceptu
advantag
approach
improv
effect
antibiot
treatment
fight
antibioticresist
bacteria
bacteri
infect
respiratori
tract
constitut
major
caus
death
worldwid
given
constant
rise
bacteri
resist
antibiot
treatment
failur
increasingli
frequent
context
innov
therapeut
strategi
urgent
need
stimul
innat
immun
cell
respiratori
tract
via
activ
tolllik
receptor
tlr
attract
approach
rapidli
activ
bodi
immun
defens
broad
spectrum
microorgan
previou
studi
agonist
flagellin
anim
model
show
standalon
tlr
stimul
result
effect
treatment
pneumococc
respiratori
infect
significantli
improv
therapeut
outcom
concomit
antibiot
treatment
investig
antibacteri
interact
antibiot
intranas
flagellin
mous
model
pneumococc
respiratori
infect
use
variou
dose
oral
administ
amoxicillin
system
administ
cotrimoxazol
found
intranas
instil
flagellin
dose
promot
maxim
lung
proinflammatori
respons
induc
synergist
rather
addit
antibacteri
effect
antibioticsuscept
pneumococcu
next
set
model
infect
pneumococcu
resist
multipl
antibiot
context
influenza
superinfect
remark
combin
amoxicillin
flagellin
effect
treat
superinfect
amoxicillinresist
pneumococcu
sinc
bacteri
clearanc
increas
compar
standalon
treatment
result
also
show
respons
flagellin
lung
tissu
gener
innat
immun
respons
even
though
damag
influenza
viru
pneumococc
infect
conclus
demonstr
select
boost
lung
innat
immun
conceptu
advantag
approach
improv
effect
antibiot
treatment
fight
antibioticresist
bacteria
keyword
flagellin
tolllik
receptor
antibiot
resist
streptococcu
pneumonia
pneumonia
superinfect
introduct
pneumonia
constitut
major
caus
death
morbid
health
resourc
use
worldwid
main
caus
agent
identifi
adult
patient
hospit
communityacquir
pneumonia
cap
virus
case
common
rhinoviru
influenza
coronaviru
bacteria
case
mark
predomin
streptococcu
pneumonia
infect
face
overt
clinic
sign
bacteri
pneumonia
standard
care
antibiot
treatment
combin
constant
rise
antibiot
resist
recent
decad
declin
discoveri
new
drug
led
increas
treatment
failur
mortal
world
health
organ
global
action
plan
highlight
urgent
need
control
emerg
antibiot
resist
given
context
number
new
antiinfecti
treatment
strategi
develop
modul
innat
immun
target
immun
receptor
tolllik
receptor
tlr
promis
approach
inde
innat
immun
highli
conserv
evolut
system
constitut
first
line
defens
invad
pathogen
moreov
innat
immun
trigger
broad
rang
antimicrobi
defens
mechan
immun
cellstherebi
greatli
reduc
risk
resist
pathogen
moreov
activ
tlr
signal
associ
favor
outcom
infect
antibioticresist
bacteria
colon
resist
pathogen
observ
support
stimul
effector
activ
innat
immun
influenc
antibiot
resist
mechan
carri
bacteria
flagellin
main
protein
compon
bacteri
flagellum
natur
agonist
latter
express
surfac
mani
differ
cell
type
includ
mucos
epitheli
cell
immun
cell
dendrit
cell
macrophag
lymphocyt
variou
studi
anim
model
highlight
antimicrobi
potenc
flagellin
wide
varieti
bacteri
infect
intestin
infect
caus
salmonella
enterica
enterococcu
faecium
clostridium
difficil
escherichia
coli
respiratori
infect
caus
pseudomona
aeruginosa
pneumonia
viral
fungal
infect
although
studi
demonstr
protect
effect
flagellin
administ
exposur
microbi
pathogen
protein
immunostimulatori
efficaci
therapeut
context
extens
character
use
mous
model
pneumonia
lung
infect
recent
demonstr
combin
treatment
mucos
administ
flagellin
oral
intraperiton
administ
lowdos
ie
subtherapeut
antibiot
effect
antibiot
alon
ie
lower
bacteri
load
lung
lower
mortal
rate
furthermor
combin
treatment
also
effect
model
postflu
pneumococc
superinfect
effect
combin
therapi
depend
signal
demonstr
use
anim
recombin
flagellin
studi
highlight
airway
epithelium
main
signal
compart
taken
whole
observ
first
highlight
ad
valu
respiratori
deliveri
flagellin
immunomodulatori
biolog
adjunct
treatment
bacteri
pneumonia
ie
addit
standard
care
work
hypothesi
simultan
treatment
antibiot
intranas
ie
respiratori
flagellin
constitut
doubl
hit
pathogen
combin
two
drug
may
result
independ
action
specif
ie
addit
synergist
antagonist
effect
defin
biolog
outcom
interact
two
drug
consid
synergist
measur
effect
combin
treatment
exce
predict
cumul
valu
two
compon
given
separ
synergi
increas
treatment
efficaci
expect
limit
emerg
drug
resist
furthermor
synergi
allow
physician
decreas
dose
level
frequenc
dose
therebi
dampen
advers
drug
reaction
may
even
enabl
rehabilit
neglect
drug
convers
antagonist
combin
treatment
smaller
effect
predict
cumul
valu
two
compon
given
separ
studi
potenti
synergist
antimicrobi
agent
perform
vitro
system
bacteri
cultur
use
checkerboard
assay
increas
dose
drug
unlik
antibiot
directli
affect
bacteria
immunomodulatori
biolog
activ
requir
sentinel
cell
detect
downstream
signal
thu
product
antimicrobi
effector
recruit
andor
activ
innat
immun
cell
present
comprehens
vitro
model
complic
physiolog
system
present
studi
quantifi
natur
magnitud
interact
antibiot
intranas
instil
flagellin
regard
antibacteri
effect
murin
model
pneumonia
respiratori
infect
furthermor
want
assess
efficaci
novel
therapeut
strategi
infect
antibioticresist
bacteria
repres
major
public
health
issu
today
aim
investig
combin
effect
antibioticresist
pneumonia
relev
model
postflu
pneumococc
pneumonia
character
immun
respons
induc
flagellinmedi
protect
serotyp
pneumonia
clinic
isol
obtain
nation
refer
laboratoryministri
health
uruguay
serotyp
pneumonia
strain
provid
institut
pasteur
pari
franc
multidrugresist
clinic
isol
human
bronchial
secret
resist
amoxicillin
amx
cefotaxim
doxycyclin
erythromycin
chloramphenicol
streptomycin
cotrimoxazol
sxt
work
stock
prepar
describ
previous
briefli
fresh
coloni
grown
bloodagar
plate
incub
todd
hewitt
yeast
broth
thyb
sigmaaldrich
saintloui
mo
c
od
reach
unit
cultur
store
c
thyb
glycerol
volvol
month
infect
work
stock
thaw
wash
steril
dulbecco
phosphatebuff
salin
pb
gibco
grand
island
ny
dilut
appropri
concentr
number
bacteria
coloni
form
unit
cfu
confirm
plate
serial
dilut
onto
sheep
blood
agar
plate
femal
balbcj
mice
femal
swiss
mice
male
mice
week
old
janvier
laboratori
saint
berthevin
franc
envigo
huntingdon
uk
maintain
individu
ventil
cage
handl
vertic
laminar
flow
cabinet
class
ii
esco
hatboro
pa
experi
compli
institut
regul
ethic
guidelin
institut
pasteur
de
lill
protocol
prior
intranas
infect
mice
anesthet
via
intraperiton
inject
mg
mgkg
ketamin
plu
mg
mgkg
xylazin
pb
primari
infect
cfu
inocul
intranas
pb
describ
previous
influenza
infect
model
develop
laboratori
mice
pneumococc
superinfect
model
therefor
perform
anim
briefli
mice
first
infect
intranas
pb
contain
plaqueform
unit
pfu
pathogen
murineadapt
influenza
viru
strain
describ
previous
seven
day
later
anim
infect
intranas
cfu
pb
determin
bacteri
count
lung
spleen
mice
sacrif
select
time
via
intraperiton
inject
mg
sodium
pentobarbit
pb
tissu
collect
homogen
ultraturrax
homogen
ikawerk
staufen
germani
viabl
count
determin
plate
serial
dilut
onto
blood
agar
plate
incub
c
h
recombin
flagellin
flic
came
enterica
serovar
typhimurium
flic
produc
histidin
tag
describ
previous
protein
flic
certifi
immunolog
activ
report
cell
mous
assay
residu
lipopolysaccharid
concentr
determin
pg
per
flagellin
treatment
effect
pneumonia
lung
infect
quantifi
percentag
bacteri
growth
growth
correspond
ratio
mean
bacteri
load
lung
infect
treat
mice
load
infect
nontreat
control
mice
exampl
effect
treatment
calcul
follow
growth
mean
cfu
mean
cfu
control
predict
addit
effect
predict
growth
combin
treatment
calcul
describ
previous
briefli
predict
growth
treatment
combin
compound
b
product
experiment
defin
growth
valu
standalon
treatment
predict
growth
ab
growth
growth
b
experiment
growth
combin
treatment
lower
higher
predict
growth
two
drug
synergist
antagonist
respect
experiment
predict
growth
valu
ident
two
drug
effect
addit
total
lung
rna
extract
nucleospin
rna
plu
kit
machereynagel
duren
germani
reversetranscrib
highcapac
cdna
archiv
kit
appli
biosystem
foster
citi
ca
cdna
amplifi
use
sybr
greenbas
realtim
pcr
quantstudio
pcr
system
appli
biosystem
rel
mrna
level
ct
determin
compar
first
pcr
cycl
threshold
c
q
gene
interest
refer
gene
actb
c
q
c
q
valu
infect
mice
treat
amxflagellin
combin
treatment
amx
alon
control
group
cq
primer
use
studi
list
tabl
valid
efficaci
bronchoalveolar
lavag
bal
fluid
sampl
obtain
intratrach
inject
ml
pb
supplement
fetal
calf
serum
fc
lung
perfus
pb
excis
fine
minc
digest
solut
rpmi
medium
gibco
contain
mgml
collagenas
viii
sigmaaldrich
dnase
sigmaaldrich
min
c
wash
red
blood
cell
remov
use
lysi
solut
pharmlys
bd
bioscienc
lung
cell
homogen
suspend
percol
gradient
centrifug
rpm
without
brake
room
temperatur
min
cell
pellet
wash
pb
supplement
fc
cell
filtrat
antibodi
label
bal
lung
cell
stain
clone
violet
clone
antisiglecfalexafluor
clone
chlorophyl
proteincyanin
clone
clone
clone
violet
clone
antibodi
dead
cell
exclud
analysi
use
propidium
iodid
antibodi
purchas
bd
bioscienc
san
jose
ca
biolegend
san
diego
ca
data
collect
bd
lsr
fortessa
analyz
bd
facsdiva
softwar
concentr
tnf
determin
bal
fluid
lung
homogen
enzymelink
immunosorb
assay
elisa
kit
ebiosci
r
system
becton
dickinson
bal
fluid
obtain
intratrach
inject
ml
pb
supplement
proteas
inhibitor
roch
lung
perfus
pb
collect
tper
reagent
pierc
supplement
proteas
inhibitor
debri
elimin
centrifug
sampl
store
c
result
describ
mean
standard
error
mean
sem
median
rang
indic
intergroup
differ
analyz
use
mannwhitney
test
log
rank
test
analys
perform
prism
softwar
version
graphpad
softwar
la
jolla
ca
threshold
statist
signific
set
p
earlier
research
shown
intranas
administr
combin
flagellin
flic
lowdos
antibiot
improv
therapeut
outcom
lung
infect
antibioticsuscept
minimum
inhibitori
concentr
mic
amx
given
difficulti
perform
vitro
checkerboard
assay
immunomodul
therefor
sought
evalu
natur
antibioticflagellin
interact
vivo
first
defin
dose
flagellin
promot
satur
immun
respons
mice
figur
intranas
administ
flagellin
associ
product
variou
innat
immunityrel
compon
includ
chemokin
inflammatori
cytokin
antimicrobi
peptid
along
recruit
neutrophil
airway
mice
treat
simultan
oral
amx
mgkg
intranas
flagellin
flic
dose
mgkg
ie
ng
per
anim
immun
respons
analyz
monitor
lung
transcript
inflammatori
gene
associ
signal
compar
mrna
level
anim
receiv
amx
alon
result
show
dose
per
anim
satur
upregul
transcript
respons
gene
ultim
dose
flic
select
satur
immunostimulatori
dose
context
pneumococc
infect
lung
inflamm
next
set
experi
design
character
therapeut
interact
intranas
flagellin
flic
oral
amx
mice
infect
treat
h
later
either
singl
intranas
instil
flagellin
singl
intragastr
administr
suboptim
amx
dose
mgkg
mgkg
combin
treatment
defin
treatment
efficaci
lung
bacteri
count
measur
h
posttreat
result
show
flagellin
alon
mostli
antibacteri
effect
wherea
dose
amx
alon
respect
associ
smaller
bacteri
load
rel
untreat
mice
figur
combin
treatment
amx
flic
induc
rel
decreas
bacteri
count
amx
rel
decreas
amxshow
amxflagellin
combin
treatment
effect
correspond
dose
amx
flagellin
monotherapi
figur
natur
interact
flagellin
antibiot
analyz
compar
bacteri
growth
upon
treatment
growth
valu
combin
treatment
flagellin
amx
flagellin
amx
much
lower
correspond
predict
growth
valu
addit
effect
calcul
growth
amx
growth
flagellin
flagellin
amx
flagellin
amx
figur
experi
indic
strong
synergi
two
compound
similar
experi
carri
combin
antibiot
sxt
flagellin
figur
antibiot
sxt
administ
intraperiton
dose
mg
mgkg
respect
flagellin
significantli
improv
therapeut
outcom
sxt
treatment
evidenc
cfu
count
mice
lung
h
administr
treatment
figur
experiment
growth
valu
combin
treatment
lower
correspond
predict
growth
valu
vs
sxt
mg
vs
sxt
mg
reflect
synergi
flagellin
sxt
figur
taken
whole
result
show
antibiot
flagellin
strong
synergist
effect
pneumococc
lung
infect
mice
furthermor
synergi
seem
independ
type
antibiot
sinc
observ
compound
inhibit
bacteri
cell
wall
amx
pair
compound
inhibit
folic
acid
synthesi
sxt
next
look
whether
combin
treatment
effect
antibioticsensit
pneumonia
strain
also
exert
antibioticresist
bacteria
end
mous
model
infect
strain
resist
wide
rang
antibiot
includ
amx
mic
amx
ie
higher
develop
found
strain
fail
induc
lethal
infect
sign
diseas
weight
loss
miceeven
high
dose
challeng
bacteria
per
anim
figur
b
given
influenza
viru
infect
increas
suscept
bacteri
infect
even
elimin
infect
assess
mice
alreadi
expos
viru
briefli
mice
infect
first
intranas
subleth
dose
viru
pfu
infect
day
later
cfu
bacteri
superinfect
induc
signific
weight
loss
lethal
figur
b
bacteri
count
increas
gradual
time
reach
cfu
per
lung
h
postinfect
figur
also
detect
spleenind
transloc
system
dissemin
bacteriafrom
h
postinfect
onward
figur
conclus
antibioticresist
strain
induc
effect
pneumonia
anim
previous
expos
experiment
flu
order
test
efficaci
antibioticflagellin
combin
treatment
postinfluenza
superinfect
model
mice
treat
amx
alon
flagellin
flic
alon
combin
compound
h
bacteri
infect
figur
due
high
level
amx
resist
dose
antibiot
use
mgkg
mgkg
use
regimen
serum
concentr
level
amx
anim
expect
close
mic
mic
respect
professor
charlott
kloft
person
commun
flagellin
treatment
alon
decreas
bacteri
count
lung
wherea
amx
treatment
decreas
bacteri
count
dose
dose
amx
combin
flagellin
bacteri
count
lower
dose
antibiot
respect
result
show
signific
therapeut
advantag
combin
treatment
rel
standalon
amx
flagellin
treatment
figur
also
determin
cfu
count
spleen
amx
amx
flagellin
treatment
either
antibiot
abl
prevent
system
dissemin
infect
data
shown
comparison
growth
observ
effect
combin
treatment
vs
predict
addit
effect
vs
amx
vs
amx
demonstr
synergi
combin
context
superinfect
antibiot
resist
figur
two
administr
treatment
h
superinfect
flagellin
amx
combin
found
significantli
improv
surviv
mice
rel
standalon
treatment
figur
data
strongli
suggest
flagellin
amx
synergist
therapeut
effect
control
antibioticresist
pneumococc
infect
relev
pathophysiolog
context
sinc
infect
influenza
viru
induc
major
chang
lung
integr
immun
cell
popul
investig
immunomodulatori
impact
flagellin
postflu
respiratori
infect
antibioticresist
strain
end
mice
infect
influenza
viru
day
challeng
antibioticresist
day
treatment
oral
amx
combin
intranas
flagellin
administ
h
infect
lung
collect
h
posttreat
transcript
analysi
use
rtqpcr
assay
describ
figur
observ
despit
superinfect
flagellin
still
enhanc
transcript
gene
ie
surrog
marker
lung
stimul
figur
next
quantifi
cytokinechemokin
product
h
treatment
bal
fluid
lung
protein
extract
deliveri
flagellin
lung
amxtreat
pneumococc
superinfect
significantli
increas
level
tumornecrosi
factor
tnf
lung
figur
bal
fluid
figur
amxflagellintr
mice
compar
amxpbstreat
mice
also
observ
increas
product
compart
although
statist
signific
product
detect
lung
tissu
increas
flagellintr
mice
final
use
flow
cytometri
evalu
immun
cell
popul
bal
fluid
lung
tissu
collect
h
posttreat
analysi
show
neutrophil
count
higher
mice
receiv
combin
treatment
ie
stimul
amx
mice
receiv
amx
alon
lung
tissu
figur
bal
fluid
figur
interestingli
innat
respons
combin
treatment
also
detect
blood
sinc
product
inflammatori
mediat
significantli
augment
h
h
compar
amx
alon
treatment
supplementari
figur
blood
cytokin
product
diminish
undetect
low
level
h
thu
observ
show
mucos
deliveri
flagellin
induc
sustain
system
inflamm
overal
innat
immun
respons
flagellin
effect
stimul
context
influenza
immunolog
imprint
superinfect
challeng
antibiot
treatment
present
result
demonstr
synergist
efficaci
combin
antibiot
amx
sxt
local
administr
immunomodulatori
biolog
flagellin
respiratori
infect
caus
pneumonia
note
efficaci
combin
antibiot
flagellin
treatment
previous
demonstr
inbr
balbc
mice
port
et
al
extend
outbr
swiss
mice
show
genet
background
independ
protect
remark
flagellin
abl
trigger
lung
innat
immun
respons
context
inflamm
ie
airway
damag
bacteri
pneumonia
flu
immunostimul
lung
dosedepend
process
satur
microgramperanim
level
flagellin
synergi
appear
independ
antibiot
dose
level
antibiot
target
sinc
amx
act
bacteri
cell
wall
sxt
inhibit
dna
synthesi
present
studi
also
first
demonstr
stimul
innat
immun
treat
sever
pneumonia
induc
antibioticresist
pathogen
bacteria
may
open
new
avenu
treatment
pneumonia
context
grow
antimicrobi
resist
demonstr
intranas
administr
flagellin
activ
local
innat
respons
broadspectrum
antibacteri
activ
pulmonari
respons
includ
product
variou
antimicrobi
peptid
ie
cathelicidin
antimicrobi
peptid
cytokin
tnf
chemokin
ie
cytokin
chemokin
product
line
observ
recruit
phagocyt
especi
neutrophil
lung
follow
intranas
administr
flagellin
mice
flagellin
intranas
administr
specif
trigger
transcript
lung
h
pneumococcu
infect
day
influenza
infect
demonstr
lung
innat
immun
signatur
induc
intranas
instil
flagellin
still
effect
highli
inflammatori
context
associ
lung
damag
pneumococc
postinfluenza
superinfect
influenc
antibiot
treatment
figur
interestingli
earlier
report
indic
influenza
infect
promot
partial
sustain
desensit
tlrmediat
lung
innat
respons
reduct
tlr
express
observ
demonstr
physiopatholog
context
superinfect
flagellin
still
abl
trigger
suffici
level
innat
defens
exert
synergi
antibiot
figur
airway
epitheli
cell
identifi
import
compon
detect
flagellin
signal
homeostasi
sentinel
cell
sens
danger
signal
introduc
conduct
airway
also
produc
factor
directli
impair
colon
growth
pathogen
indirectli
mobil
phagocyt
immun
cell
clear
infect
gener
airway
epithelium
tlr
signal
repres
key
drive
forc
antibacteri
defens
recent
ana
et
al
demonstr
essenti
contribut
epitheli
signal
respiratori
tract
respons
flagellin
context
infect
pseudomona
aeruginosa
data
show
sever
antimicrobi
peptid
cytokin
tnf
chemokin
associ
epitheli
respons
also
upregul
administr
combin
treatment
postflu
superinfect
model
suggest
epithelium
also
import
flagellinspecif
drive
forc
lung
damag
viral
bacteri
infect
target
epithelium
seriou
benefit
immunostimul
sinc
allow
reduc
dose
bypass
system
advers
effect
data
contribut
highlight
therapeut
potenti
associ
two
drug
distinct
mode
action
antibiot
direct
effect
bacteria
stimul
innat
immun
indirect
antibacteri
activ
mobil
multipl
phagocyt
host
cell
variou
antimicrobi
factor
antibacteri
peptid
chemokin
cytokin
mobil
activ
immun
cell
besid
pathogen
kill
multitarget
innat
immun
flagellin
could
impact
bacteri
fit
therebi
increas
suscept
antibiot
innat
immun
respons
induc
signal
may
also
modifi
distribut
antibiot
lung
tissu
antibiot
damag
pathogen
could
also
enhanc
immun
signal
addit
pharmacokinet
antibiot
immunostimul
ie
shortterm
dosedepend
effect
antibiot
immedi
longlast
impact
immunostimul
due
cell
mobil
like
complementari
final
flagellin
modul
innat
immun
respiratori
tract
shown
enhanc
mucos
system
adapt
immun
properti
may
interest
elicit
antipathogen
immun
memori
prevent
recurrentrelaps
infect
opportunist
bacterium
pneumonia
frequent
colon
upper
respiratori
tract
thu
repres
lung
collect
h
treatment
homogen
rna
extract
express
level
select
gene
analyz
use
rtqpcr
assay
rel
express
level
gene
express
refer
gene
actb
refer
condit
amxpb
arbitrarili
set
valu
data
repres
mean
sem
lung
b
bal
fluid
c
collect
h
treatment
cytokin
continu
figur
chemokin
level
measur
elisa
data
amxflagellintr
amxpbstreat
mice
compar
mannwhitney
test
repres
individu
valu
mean
lung
bal
e
collect
h
treatment
lung
bal
cell
suspens
stain
use
mixtur
antibodi
specif
surfac
marker
flow
cytometri
analysi
neutrophil
defin
cell
exclus
dead
cell
alveolar
macrophag
siglecf
cell
analysi
number
neutrophil
lung
parenchyma
bal
fluid
e
shown
individu
anim
line
repres
mean
data
amxflagellin
group
compar
amxpb
group
mannwhitney
test
statist
signific
indic
follow
p
p
prime
caus
bacterialassoci
cap
howev
microorgan
caus
cap
healthcareassoci
pneumonia
includ
gramposit
bacteria
staphylococcu
aureu
gramneg
bacteria
like
p
aeruginosa
klebsiella
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
intracellular
bacteria
legionella
pneumophila
diagnosi
treatment
cap
complic
broad
varieti
caus
agent
progress
antibacteri
resist
context
immunomodul
flagellin
great
interest
activ
larg
number
antimicrobi
immun
mechan
inde
flagellin
alreadi
demonstr
abil
protect
variou
pathogen
includ
gramneg
gramposit
bacteria
furthermor
present
result
show
therapeut
synergi
antibiot
intranas
flagellin
independ
antibiot
mechan
actionsuggest
flagellin
potenti
combin
variou
antibiot
wide
rang
clinic
situat
synergist
effect
combin
therapi
determin
independ
capsul
antigen
serotyp
pneumococcu
suggest
gener
innat
immun
protect
mechan
trigger
flagellin
could
potenti
effect
larg
varieti
serotyp
given
progress
antibiot
resist
model
infect
antibioticresist
bacteria
would
constitut
import
tool
develop
altern
antiinfecti
approach
first
attempt
develop
model
immunocompet
anim
multidrugresist
clinic
isol
pneumococcu
unabl
induc
lethal
infect
even
high
dose
acquisit
antibiot
resist
often
associ
loss
bacteri
fit
might
explain
low
virul
mice
becom
clear
mani
case
bacteri
pneumonia
result
coinfect
consecut
infect
especi
influenza
viru
infect
shown
figur
e
influenza
viru
infect
creat
favor
environ
colon
invas
lowvirul
antibioticresist
pneumococcu
strain
data
demonstr
flagellinamx
combin
treatment
effect
reduc
bacteri
burden
caus
strain
lung
improv
surviv
rate
among
treat
mice
proofofconcept
find
may
transpos
clinic
patient
coinfect
superinfect
relev
physiopatholog
caus
hospit
complic
pneumonia
antibiot
constitut
current
standard
care
bacteri
pneumonia
grow
threat
antibiot
resist
major
public
health
concern
defin
dose
regiment
antibiot
use
treat
patient
physician
must
take
account
antibiot
pharmacokinet
pharmacodynam
characterist
relationship
vivo
exposur
drug
vitro
suscept
bacteria
condit
treatment
clinic
outcom
ie
clearanc
infect
also
advers
effect
drug
toxic
thu
maximum
dose
antibiot
administ
patient
may
enough
total
clear
highli
resist
bacteria
data
suggest
antibacteri
efficaci
antibiot
dose
level
synergist
enhanc
effect
flagellin
lung
innat
immun
taken
whole
present
result
suggest
select
boost
innat
lung
immun
flagellin
improv
therapeut
outcom
antibiot
treatment
human
approach
might
use
gener
altern
treatment
bacteri
pneumonia
therebi
reduc
antibiot
dose
regimen
well
emerg
antibiot
resist
moreov
strategi
promot
multitarget
inhibit
multipl
innat
immun
effector
resist
develop
resist
may
restor
antibacteri
activ
antibiot
context
antibiot
resist
character
flagellin
contribut
lung
antibacteri
defens
molecular
cellular
level
protein
synergi
antibiot
like
open
new
avenu
immunotherapi
respiratori
tract
infect
experi
compli
institut
regul
ethic
guidelin
institut
pasteur
de
lill
protocol
apafi
protocol
valid
ethic
committe
anim
experi
en
animalenordpasdecalai
ceea
lm
perform
anim
rtqpcr
flow
cytometri
experi
fc
rp
dc
cf
provid
lm
technic
assist
fw
analyz
bacteri
speci
antibiot
resist
lm
cc
jc
design
experi
wrote
manuscript
jc
cc
supervis
experiment
work
whole
studi
fund
inserm
institut
pasteur
de
lill
de
lill
insermtransfert
grant
copoc
innatebiot
eranet
joint
program
initi
antimicrobi
resist
agenc
national
de
la
recherch
grant
lm
fellow
innov
pharmaceutiqu
et
recherch
program
